riTUXimab 375 mg/m2 Combination Therapy-21 day. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Regulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| In combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory CD 20 positive patients with follicular lymphoma. |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.
| Organizations | Biomarkers | Cancer types | Therapies |
|---|